Purine derivatives for the treatment of viral infections

• US 10,280,167 B2
• Filed: 01/30/2017
• Issued: 05/07/2019
• Est. Priority Date: 11/09/2011
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Original Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Inventors: Bonfanti, Jean-Francois, Doublet, Frederic Marc Maurice, Embrechts, Werner, Fortin, Jerome Michel Claude, McGowan, David Craig, Muller, Philippe, Raboisson, Pierre Jean-Marie Bernard
• Primary Examiner(s): Fetterolf, Brandon J
• Assistant Examiner(s): Matos Negron, Taina D
• Application Number:
  US15/420,045
• Publication Number:
  US 20170283419A1
• Time in Patent Office: 827 Days
• Field of Search: 514183
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 473/16 two nitrogen atoms
• CPC Class Codes: C07D 473/34 attached in position 6, e.g. adenine
• CPC Class Codes: C07D 519/00 Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• CPC Class Codes: C07F 9/65616 containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Abstract

The present invention relates to purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Claims

1. A method for activating TLR7 in a subject comprising administering to said subject an effective amount of a compound

selected from the group consisting of

2. A method for inducing interferon production in a subject, comprising administering to said subject an effective amount of a compound

selected from the group consisting of

3. A method of activating TLR7 in a subject treated for a viral infection comprising administering to said subject a pharmaceutical compositions comprising a compound

selected from the group consisting of

4. A method of inducing interferon production in a subject treated for a viral infection comprising administering to said subject a pharmaceutical composition comprising a compound

selected from the group consisting of